Insulin growth factor-like family member 1 (IGFL1)

Insulin growth factor-like family member 1 (IGFL1) is a secreted protein belonging to the IGF-like protein family and structurally related to insulin-like growth factors. IGFL1 binds with high affinity to IGFLR1 (Insulin growth factor-like family receptor 1, also called TMEM149), a transmembrane protein with homology to the tumor necrosis factor receptor (TNFR) family[1][3]. IGFL1 is encoded on human chromosome 19 and is primarily expressed in fetal epithelial tissues, inflamed skin, and a range of tumors[1][3][4]. Its upregulation is associated with cancer cell proliferation, epithelial–mesenchymal transition (EMT), immune suppression, and poor prognosis, especially in bladder, breast, and ovarian cancer[2][1]. Mechanistically, IGFL1 promotes tumor progression and immune evasion, likely via the JAK2/STAT3 pathway[2]. While no approved drugs yet target IGFL1, its molecular characteristics, expression patterns, and pathological involvement make it a promising candidate for prognostic biomarker development and as a therapeutic target in oncology and immunology[2][3].

Other names

IGFL1Insulin growth factor-like family member 1UNQ644/PRO1274UNQ644APRG644

No drugs directly targeting IGFL1. However, downstream pathway effects suggest that inhibition (e.g., by RNAi or gene silencing in models) impacts proliferation and apoptosis, particularly via the JAK2/STAT3 signaling pathway[2]. - Immunomodulatory effects (potentially by altering tumor immunogenicity or immune checkpoint signaling)[2].